April 22, 2020 11:12 AM EDT
News Briefing

EMA ap­proves Boehringer's sys­temic scle­ro­sis ther­a­py; No­var­tis' Kym­ri­ah wins RMAT sta­tus for fol­lic­u­lar lym­phoma

ENDPOINTS

→ The Eu­ro­pean Com­mis­sion has ap­proved Boehringer In­gel­heim‘s nintedanib for sys­temic scle­ro­sis-as­so­ci­at­ed in­ter­sti­tial lung dis­ease (SSc-ILD) in adults. The OK …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times